GlassScriptPhysician profile
Danielle Alhemovich
NPI 1831552611
$2,498.41
in general payments reported to CMS, 2019-2025
30 companies · $28.75 in 2025
The $28.75 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $393 · 2021: $618 · 2022: $376 · 2023: $261 · 2024: $711 · 2025: $28.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $435.90 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $341.07 | 2020-2024 | Farxiga |
| Abbott Laboratories | $289.02 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $162.92 | 2020-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $144.65 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $116.87 | 2023 | Nuedexta |
| Abbvie INC. | $99.09 | 2021-2022 | |
| Amarin Pharma, INC. | $89.87 | 2020-2022 | |
| Amgen INC. | $86.06 | 2020-2022 | |
| Esperion Therapeutics, INC. | $78.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.41 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $69.86 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.71 | 2021-2023 | |
| Lilly USA, LLC | $64.65 | 2023-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $59.30 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $43.77 | 2021 | |
| Jazz Pharmaceuticals INC. | $42.79 | 2021-2022 | |
| Glaxosmithkline, LLC. | $35.72 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $28.75 | 2025 | Opsynvi, Uptravi |
| Mylan Specialty L.P. | $27.11 | 2020-2021 | |
| Antares Pharma, INC. | $16.82 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.90 | 2022 | |
| Phadia US INC. | $14.66 | 2021 | |
| Clarus Therapeutics INC. | $13.74 | 2021 | |
| Endo Pharmaceuticals INC. | $13.57 | 2021 | |
| Allergan, INC. | $12.76 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.57 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.55 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Alhemovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.